StockData
Maravai LifeSciences Holdings, Inc. logo

Maravai LifeSciences Holdings, Inc. (MRVI) stock

MRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30170% above fair value
$7.40−0.14 (-1.86%)

Close on Nov 16, 2026Market cap $1.92BP/E –Yield –

Maravai LifeSciences gross margin

Gross margin is gross profit as a percentage of revenue.

Maravai LifeSciences's gross margin for the twelve months ending Jun 30, 2026 was 34.9%. For fiscal 2025 it was 18.3%, against 41.8% the year before. The highest annual figure on record is 82.4% in fiscal 2021.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202518.3%−23.5
FY2024Dec 31, 202441.8%−6.7
FY2023Dec 31, 202348.5%−32.3
FY2022Dec 31, 202280.9%−1.5
FY2021Dec 31, 202182.4%+10.4
FY2020Dec 31, 202072.0%+18.7
FY2019Dec 31, 201953.3%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202640.1%+23.8
Q1 FY2026Mar 31, 202651.2%+34.7
Q4 FY2025Dec 31, 202525.8%−8.5
Q3 FY2025Sep 30, 202513.6%−33.1
Q2 FY2025Jun 30, 202516.4%−28.0
Q1 FY2025Mar 31, 202516.5%−23.8
Q4 FY2024Dec 31, 202434.3%−18.4
Q3 FY2024Sep 30, 202446.7%+1.6
Q2 FY2024Jun 30, 202444.4%+7.2
Q1 FY2024Mar 31, 202440.3%−17.1
Q4 FY2023Dec 31, 202352.6%−21.3
Q3 FY2023Sep 30, 202345.1%−34.9
Q2 FY2023Jun 30, 202337.2%−47.3
Q1 FY2023Mar 31, 202357.4%−26.2
Q4 FY2022Dec 31, 202274.0%−8.9
Q3 FY2022Sep 30, 202280.0%−4.2
Q2 FY2022Jun 30, 202284.6%+1.9
Q1 FY2022Mar 31, 202283.6%+4.8
Q4 FY2021Dec 31, 202182.9%+6.7
Q3 FY2021Sep 30, 202184.3%+6.8
Q2 FY2021Jun 30, 202182.6%+27.8
Q1 FY2021Mar 31, 202178.8%+8.8
Q4 FY2020Dec 31, 202076.2%–
Q3 FY2020Sep 30, 202077.5%–
Q2 FY2020Jun 30, 202054.8%–
Q1 FY2020Mar 31, 202070.0%–

More Maravai LifeSciences figures

See a number that looks wrong?